Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 1.33
CRME's Cash to Debt is ranked lower than
78% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. CRME: 1.33 )
Ranked among companies with meaningful Cash to Debt only.
CRME' s Cash to Debt Range Over the Past 10 Years
Min: 0.64  Med: 84.26 Max: No Debt
Current: 1.33
Equity to Asset 0.44
CRME's Equity to Asset is ranked lower than
76% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. CRME: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
CRME' s Equity to Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.77 Max: 0.99
Current: 0.44
-0.01
0.99
F-Score: 4
Z-Score: -9.07
M-Score: -2.66
WACC vs ROIC
10.04%
-140.42%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -91.15
CRME's Operating margin (%) is ranked lower than
52% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -72.99 vs. CRME: -91.15 )
Ranked among companies with meaningful Operating margin (%) only.
CRME' s Operating margin (%) Range Over the Past 10 Years
Min: -4322.53  Med: -277.79 Max: 55.51
Current: -91.15
-4322.53
55.51
Net-margin (%) -96.87
CRME's Net-margin (%) is ranked lower than
54% of the 733 Companies
in the Global Biotechnology industry.

( Industry Median: -74.36 vs. CRME: -96.87 )
Ranked among companies with meaningful Net-margin (%) only.
CRME' s Net-margin (%) Range Over the Past 10 Years
Min: -3773.07  Med: -145.95 Max: 105.81
Current: -96.87
-3773.07
105.81
ROE (%) -120.09
CRME's ROE (%) is ranked lower than
86% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -31.54 vs. CRME: -120.09 )
Ranked among companies with meaningful ROE (%) only.
CRME' s ROE (%) Range Over the Past 10 Years
Min: -142.44  Med: -83.14 Max: 116.11
Current: -120.09
-142.44
116.11
ROA (%) -47.00
CRME's ROA (%) is ranked lower than
68% of the 944 Companies
in the Global Biotechnology industry.

( Industry Median: -26.66 vs. CRME: -47.00 )
Ranked among companies with meaningful ROA (%) only.
CRME' s ROA (%) Range Over the Past 10 Years
Min: -101.59  Med: -40.11 Max: 51.35
Current: -47
-101.59
51.35
ROC (Joel Greenblatt) (%) -463.87
CRME's ROC (Joel Greenblatt) (%) is ranked lower than
53% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -357.95 vs. CRME: -463.87 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRME' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1661.83  Med: -798.24 Max: 1549.87
Current: -463.87
-1661.83
1549.87
Revenue Growth (3Y)(%) 190.90
CRME's Revenue Growth (3Y)(%) is ranked higher than
98% of the 491 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. CRME: 190.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRME' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -75.5  Med: 42.15 Max: 271.5
Current: 190.9
-75.5
271.5
EBITDA Growth (3Y)(%) 13.40
CRME's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 493 Companies
in the Global Biotechnology industry.

( Industry Median: -0.70 vs. CRME: 13.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRME' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -47.4  Med: -1.80 Max: 27.2
Current: 13.4
-47.4
27.2
EPS Growth (3Y)(%) 7.60
CRME's EPS Growth (3Y)(%) is ranked higher than
66% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. CRME: 7.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRME' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.9  Med: -1.50 Max: 144.6
Current: 7.6
-68.9
144.6
» CRME's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

CRME Guru Trades in Q2 2015

Jim Simons 91,647 sh (-5.63%)
» More
Q3 2015

CRME Guru Trades in Q3 2015

Jim Simons 66,613 sh (-27.32%)
» More
Q4 2015

CRME Guru Trades in Q4 2015

Jim Simons 62,213 sh (-6.61%)
» More
Q1 2016

CRME Guru Trades in Q1 2016

Jim Simons 65,313 sh (+4.98%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:FBIO, TPE:1734, XPAR:CEREN, XBRU:THR, XKRX:067370, XKRX:142760 » details
Traded in other countries:COM.Canada, CKO1.Germany,
Cardiome Pharma Corp is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Cardiome Pharma Corp was incorporated on December 12, 1986. The Company is a specialty pharmaceutical company engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It currently has two marketed, in-hospital, cardiology products, BRINAVESS, for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adultsand and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in Acute Coronary Syndrome patients. Both of its products are commercially available in numerous markets outside of the United States. BRINAVESS was approved in September 2010 and has been launched in the European Union, Iceland and Norway.

Ratios

vs
industry
vs
history
P/B 4.74
CRME's P/B is ranked lower than
69% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. CRME: 4.74 )
Ranked among companies with meaningful P/B only.
CRME' s P/B Range Over the Past 10 Years
Min: 1.02  Med: 6.89 Max: 33.74
Current: 4.74
1.02
33.74
P/S 3.76
CRME's P/S is ranked higher than
77% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. CRME: 3.76 )
Ranked among companies with meaningful P/S only.
CRME' s P/S Range Over the Past 10 Years
Min: 3.19  Med: 21.40 Max: 303.15
Current: 3.76
3.19
303.15
Current Ratio 1.93
CRME's Current Ratio is ranked lower than
76% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. CRME: 1.93 )
Ranked among companies with meaningful Current Ratio only.
CRME' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 7.19 Max: 97.75
Current: 1.93
1.14
97.75
Quick Ratio 1.64
CRME's Quick Ratio is ranked lower than
76% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. CRME: 1.64 )
Ranked among companies with meaningful Quick Ratio only.
CRME' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 7.19 Max: 97.75
Current: 1.64
1.07
97.75
Days Inventory 252.00
CRME's Days Inventory is ranked lower than
80% of the 446 Companies
in the Global Biotechnology industry.

( Industry Median: 127.50 vs. CRME: 252.00 )
Ranked among companies with meaningful Days Inventory only.
CRME' s Days Inventory Range Over the Past 10 Years
Min: 207.9  Med: 246.22 Max: 1286.27
Current: 252
207.9
1286.27
Days Sales Outstanding 137.62
CRME's Days Sales Outstanding is ranked lower than
82% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. CRME: 137.62 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRME' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.04  Med: 127.18 Max: 540.02
Current: 137.62
4.04
540.02
Days Payable 129.28
CRME's Days Payable is ranked higher than
76% of the 435 Companies
in the Global Biotechnology industry.

( Industry Median: 58.35 vs. CRME: 129.28 )
Ranked among companies with meaningful Days Payable only.
CRME' s Days Payable Range Over the Past 10 Years
Min: 192.5  Med: 199.26 Max: 2230.17
Current: 129.28
192.5
2230.17

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 19.75
CRME's Price/Net Current Asset Value is ranked lower than
88% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. CRME: 19.75 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRME' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.11  Med: 7.55 Max: 279.5
Current: 19.75
1.11
279.5
Price/Tangible Book 18.23
CRME's Price/Tangible Book is ranked lower than
91% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. CRME: 18.23 )
Ranked among companies with meaningful Price/Tangible Book only.
CRME' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 7.17 Max: 232.17
Current: 18.23
1.11
232.17
Price/Median PS Value 0.18
CRME's Price/Median PS Value is ranked higher than
94% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. CRME: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
CRME' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.16  Med: 1.74 Max: 80
Current: 0.18
0.16
80
Earnings Yield (Greenblatt) (%) -22.21
CRME's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. CRME: -22.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CRME' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -21.82  Med: 6.00 Max: 669494.2
Current: -22.21
-21.82
669494.2

More Statistics

Revenue (TTM) (Mil) $22.50
EPS (TTM) $ -1.17
Beta1.58
Short Percentage of Float0.87%
52-Week Range $3.70 - 10.40
Shares Outstanding (Mil)20.35

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 37 56 82
EPS ($) -0.89 -0.34 0.28
EPS without NRI ($) -0.89 -0.34 0.28
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for CRME

Headlines

Articles On GuruFocus.com
A Closer Look Into Veritas Pharma Apr 21 2016 
Julian Robertson’s "smart idea, grounded on exhaustive research, followed by a big bet" Jun 24 2011 
Julian Robertson’s Tiger Management Q1 Portfolio Update May 16 2011 
Julian Robertson Keeps Buying CRME, Selling AAPL Apr 13 2011 
More Word of Wisdom from Julian Robertson; Top 2Q10 Purchases: GOOG, EBAY, AAPL, CRME, GS Nov 04 2010 

More From Other Websites
Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 May 23 2016
Cardiome Pharma (CRME) Jumps: Stock Moves 8.1% Higher May 23 2016
Cardiome Reports First Quarter 2016 Financial Results May 13 2016
Cardiome reports 1Q loss May 13 2016
Cardiome reports 1Q loss May 13 2016
Cardiome Reports First Quarter 2016 Financial Results May 13 2016
Cardiome Reports First Quarter 2016 Financial Results May 13 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France May 12 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France May 12 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France May 12 2016
Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study May 11 2016
Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 May 11 2016
Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study May 11 2016
Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 May 11 2016
Cardiome Announces Publication of Spanish Emergency Department BRINAVESS Study May 11 2016
Cardiome to Hold First Quarter 2016 Financial Results Conference Call on May 13 May 11 2016
Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More May 10 2016
Cardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets May 05 2016
Cardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets May 05 2016
Cardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets May 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)